Anebulo Pharmaceuticals, INC

Anebulo Pharmaceuticals announced its decision to voluntarily delist from Nasdaq and deregister with the SEC, citing high costs, while reporting Q2 FY26 financial results.

Anebulo Pharmaceuticals, Inc. announced its board approved the voluntary delisting of its common stock from Nasdaq and subsequent deregistration with the SEC to suspend reporting obligations.

Anebulo Pharmaceuticals announced the final results of its tender offer, repurchasing 300,000 shares at $3.50 each for approximately $1.05 million.

Anebulo Pharmaceuticals announced preliminary results of its oversubscribed tender offer to repurchase 300,000 shares of common stock at $3.50 per share.

Anebulo Pharmaceuticals announces a cash tender offer to buy back 300,000 shares at $3.50 each, abandoning a costly reverse stock split as part of its plan to go private.

Anebulo Pharmaceuticals announced its first quarter fiscal year 2026 financial results and provided updates on its lead drug candidate, selonabant, for pediatric cannabis toxicity.

Anebulo Pharmaceuticals reports reduced net loss and a strategic shift to pediatric cannabis toxicity treatment, while initiating a going-private transaction.

Anebulo Pharmaceuticals reports a reduced net loss for Q1 2026, pivots its lead drug development to pediatric cannabis toxicity, and is actively reviewing strategic alternatives including a proposed going-private transaction.

Anebulo Pharmaceuticals focuses on developing intravenous selonabant for pediatric cannabis-induced toxicity while reporting financial results for the quarter ended March 31, 2025.

Anebulo Pharmaceuticals focuses on developing intravenous selonabant for pediatric cannabis toxicity while reporting a net loss of $4.66 million for the six months ended December 31, 2024.

Anebulo Pharmaceuticals reported a net loss of $2.2 million for the quarter ended September 30, 2024, and is prioritizing the development of an intravenous formulation of selonabant for pediatric cannabis toxicity.

Anebulo Pharmaceuticals reported its Q3 2024 financial results, highlighting a net loss and a strategic shift to prioritize an intravenous treatment for pediatric cannabis poisoning.

Anebulo Pharmaceuticals is prioritizing the development of an intravenous selonabant formulation for pediatric cannabis poisoning, while reporting continued operating losses and proposing a reverse stock split to go private.

Anebulo Pharmaceuticals shifts focus to an intravenous formulation of selonabant for pediatric cannabis poisoning, citing faster approval potential and a critical unmet need.

Director Joseph F. Lawler reports acquisition of stock options in Anebulo Pharmaceuticals.

Bimal R. Shah, a director at Anebulo Pharmaceuticals, received stock options and granted a limited power of attorney for Section 16 reporting obligations.

Kenneth C. Cundy, Chief Scientific Officer of Anebulo Pharmaceuticals, was granted stock options and has filed a power of attorney for Section 16 reporting.

Jason Aryeh, a director of Anebulo Pharmaceuticals, acquired stock options for 29,964 shares on April 4, 2025.

Richard Anthony Cunningham, CEO of Anebulo Pharmaceuticals, acquired stock options for 316,352 shares at an exercise price of $1.02 on April 4, 2025, according to a Form 4 filing.

Director Kenneth Lin acquired stock options in Anebulo Pharmaceuticals, Inc. on April 4, 2025.

Anebulo Pharmaceuticals is asking stockholders to vote on key proposals at its upcoming annual meeting, including declassifying the board, increasing authorized shares, and amending the stock incentive plan.

Anebulo Pharmaceuticals, Inc. announces that Aron R. English and affiliated entities now beneficially own 51.1% of its common stock, following a private placement and new lock-up and support agreements.

Nantahala Capital Management and its managing members disclosed an 8.53% beneficial ownership stake in Anebulo Pharmaceuticals, including exercisable warrants.

Mangrove Partners IM, LLC and Nathaniel August have reported a passive beneficial ownership of 6.15% of Anebulo Pharmaceuticals, Inc.'s common stock as of December 31, 2024.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 8.63% in Anebulo Pharmaceuticals, Inc. as of December 31, 2024.